Literature DB >> 20059565

Venous access in haemophilic children: choice and management.

E Santagostino1, M E Mancuso.   

Abstract

Current haemophilia treatment in children is based on regular intravenous infusions of concentrates for prolonged periods, according to prophylaxis regimens or immune tolerance induction treatment, in cases of inhibitor development. Therefore, a stable and uncomplicated venous access is required and as such peripheral veins represent the preferred option. However, frequent infusions in the home setting can be problematic in very young children and for this reason, central venous access devices (CVADs) have been widely used to improve treatment feasibility. Unfortunately CVADs' use is associated with a high rate of complications, and infections and thrombotic occlusion can influence treatment outcome by causing unwanted treatment interruption. CVADs can be grouped into three main categories: external non-tunnelled, external tunnelled and fully implantable devices known as ports. The management of CVADs at home often represents a challenge because a strict adherence to sterile procedures is required. Indeed, the incidence of infections with ports is much lower than that reported for external devices; however, ports carry the inconvenience of needle sticks. More recently, arteriovenous fistula was shown to be a suitable alternative to CVADs because it is easy to use and is associated with a lower rate of complication.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20059565     DOI: 10.1111/j.1365-2516.2009.02156.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  11 in total

Review 1.  Practical aspects of extended half-life products for the treatment of haemophilia.

Authors:  Thierry Lambert; Gary Benson; Gerry Dolan; Cedric Hermans; Victor Jiménez-Yuste; Rolf Ljung; Massimo Morfini; Silva Zupančić-Šalek; Elena Santagostino
Journal:  Ther Adv Hematol       Date:  2018-09-06

2.  Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial.

Authors:  Elena Santagostino; Uri Martinowitz; Toshko Lissitchkov; Brigitte Pan-Petesch; Hideji Hanabusa; Johannes Oldenburg; Lisa Boggio; Claude Negrier; Ingrid Pabinger; Mario von Depka Prondzinski; Carmen Altisent; Giancarlo Castaman; Koji Yamamoto; Maria-Teresa Álvarez-Roman; Christine Voigt; Nicole Blackman; Iris Jacobs
Journal:  Blood       Date:  2016-01-11       Impact factor: 22.113

3.  Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results.

Authors:  Amy D Shapiro; Pantep Angchaisuksiri; Jan Astermark; Gary Benson; Giancarlo Castaman; Pratima Chowdary; Hermann Eichler; Victor Jiménez-Yuste; Kaan Kavakli; Tadashi Matsushita; Lone Hvitfeldt Poulsen; Allison P Wheeler; Guy Young; Silva Zupancic-Salek; Johannes Oldenburg
Journal:  Blood       Date:  2019-11-28       Impact factor: 22.113

4.  Gene therapy for haemophilia.

Authors:  Akshay Sharma; Manu Easow Mathew; Vasumathi Sriganesh; Ulrike M Reiss
Journal:  Cochrane Database Syst Rev       Date:  2020-04-28

Review 5.  Gene therapy for haemophilia.

Authors:  Akshay Sharma; Manu Easow Mathew; Vasumathi Sriganesh; Ulrike M Reiss
Journal:  Cochrane Database Syst Rev       Date:  2016-12-20

6.  Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients.

Authors:  Elena Santagostino; Claude Negrier; Robert Klamroth; Andreas Tiede; Ingrid Pabinger-Fasching; Christine Voigt; Iris Jacobs; Massimo Morfini
Journal:  Blood       Date:  2012-08-02       Impact factor: 22.113

7.  Successful immune tolerance induction consisting of high-dose factor VIII rich in von Willebrand factor and pulsed intravenous immunoglobulin: a case report.

Authors:  Peter Kubisz; Ivana Plamenova; Pavol Holly; Jan Stasko
Journal:  J Med Case Rep       Date:  2012-10-11

Review 8.  Past, present and future of hemophilia: a narrative review.

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Orphanet J Rare Dis       Date:  2012-05-02       Impact factor: 4.123

9.  Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children. Results of a phase 3 trial.

Authors:  Gili Kenet; Hervé Chambost; Christoph Male; Thierry Lambert; Susan Halimeh; Tatiana Chernova; Maria Elisa Mancuso; Julie Curtin; Christine Voigt; Yanyan Li; Iris Jacobs; Elena Santagostino
Journal:  Thromb Haemost       Date:  2016-09-01       Impact factor: 5.249

Review 10.  Issues in pediatric haemophilia care.

Authors:  Paola Giordano; Massimo Franchini; Giuseppe Lassandro; Maria Felicia Faienza; Roberto Valente; Angelo Claudio Molinari
Journal:  Ital J Pediatr       Date:  2013-04-20       Impact factor: 2.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.